US still expects to meet vaccine target despite Johnson & Johnson issues

The US still expects to meet its target for delivering COVID-19 vaccines despite Johnson & Johnson struggling with production, a White House senior aide said Monday.

Andy Slavitt, a senior adviser to President Biden’s coronavirus response team, said that the drugmaker is still on track to deliver 24 million doses in April. “You can expect even without additional doses from Johnson & Johnson for us to be somewhere in that neighborhood,” Slavitt said at a coronavirus press briefing.